GlassScriptPhysician profile
Geriann C Meandro
NPI 1740350016
$2,612.95
in general payments reported to CMS, 2019-2025
36 companies · $931 in 2025
The $931 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $84.50 · 2023: $125 · 2024: $1,145 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $210.41 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $192.79 | 2023-2025 | Tagrisso, Imfinzi |
| Genzyme Corporation | $154.63 | 2025 | |
| Jazz Pharmaceuticals INC. | $149.84 | 2024-2025 | |
| Incyte Corporation | $140.54 | 2025 | Jakafi, Pemazyre, Monjuvi |
| Biomarin Pharmaceutical INC. | $124.97 | 2024 | Roctavian |
| Glaxosmithkline, LLC. | $122.80 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $118.23 | 2024 | Fruzaqla, Ninlaro, Alunbrig |
| Epizyme, INC. | $117.25 | 2021 | |
| Genentech USA, INC. | $112.06 | 2021-2024 | Polivy |
| Novartis Pharmaceuticals Corporation | $97.99 | 2021-2025 | |
| Boston Scientific Corporation | $96.23 | 2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $95.63 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $86.98 | 2021 | |
| Servier Pharmaceuticals LLC | $84.50 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $79.80 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $75.02 | 2024-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.45 | 2024 | Gilotrif |
| Gilead Sciences, INC. | $48.10 | 2024-2025 | Trodelvy |
| Kite Pharma, INC. | $48.07 | 2024 | Yescarta |
| Lilly USA, LLC | $39.57 | 2024-2025 | Verzenio, Jaypirca |
| Celgene Corporation | $38.85 | 2025 | Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $34.40 | 2025 | |
| Taiho Oncology, INC. | $32.63 | 2025 | |
| Eisai INC. | $31.45 | 2024-2025 | |
| Tersera Therapeutics LLC | $28.36 | 2024 | Zoladex |
| Daiichi Sankyo INC. | $27.73 | 2024 | Enhertu |
| Kyowa Kirin, INC. | $23.74 | 2024 | Poteligeo |
| Sobi, INC | $22.95 | 2024 | |
| Syndax Pharmaceuticals, INC. | $21.72 | 2025 | |
| Myriad Genetic Laboratories, INC. | $21.20 | 2025 | Myrisk |
| Beone Medicines USA, INC. | $20.15 | 2025 | Tevimbra |
| Sumitomo Pharma America, INC. | $16.55 | 2025 | Orgovyx |
| Array Biopharma INC | $16.09 | 2024 | Mektovi, Lorbrena, Braftovi |
| E.R. Squibb & Sons, L.L.C. | $13.86 | 2025 | Opdivo |
| Ge Healthcare | $9.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geriann Meandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.